MELAS and L-arginine therapy
MELAS and L-arginine therapy
复制标题
DOI：
10.1016/j.mito.2006.11.006
复制
发表时间：
2007-02-01
期刊：
影响因子：
4.4
通讯作者：
Matsuishi, Toyojiro
中科院分区：
文献类型：
--
作者：
Koga, Yasutoshi;Akita, Yukhiro;Matsuishi, Toyojiro
我们研究了MELAS患者的内皮功能，并评估了L-精氨酸的治疗效果。MELAS急性期L-精氨酸浓度显着低于对照受试者。L-精氨酸输注在30分钟内显著改善了所有提示卒中的症状，口服给药显著降低了卒中样发作的频率和严重程度。患者的血流介导性舒张功能（FMD）较对照组明显降低。两年的口服补充L-精氨酸显着改善内皮功能的控制水平，并与患者的L-精氨酸的正常血浆水平相协调。L-精氨酸治疗在MELAS中显示出治疗卒中样发作的前景。(c)2007 Elsevier B. V.和线粒体研究学会。All rights reserved.
We investigated the endothelial function in MELAS patients and also evaluated the therapeutic effects of L-arginine. Concentrations of L-arginine during the acute phase of MELAS were significantly lower than in control subjects. L-arginine infusions significantly improved all symptoms suggesting stroke within 30 min, and oral administration significantly decreased frequency and severity of stroke-like episodes. Flow-mediated dilation (FMD) in patients showed a significant decrease than those in the controls. Two years of oral supplementation of L-arginine significantly improved endothelial function to the control levels and was harmonized with the normalized plasma levels of L-arginine in patients. L-arginine therapy showed promise in treating stroke-like episodes in MELAS. (c) 2007 Elsevier B.V. and Mitochondria Research Society. All rights reserved.